ompared to individuals without diabetes mellitus (DM), DM patients have approximately a 2-fold higher risk of short-term mortality after acute myocardial infarction (AMI). 1, 2 In the current reperfusion era, over 90% of DM patients survive the early 30-day period; however, these patients are prone to markedly-increased mortality after 6 th months. 3, 4 The results of several clinical studies indicate that even people with pre-diabetic conditions, such as impaired glucose tolerance (IGT), have increased risks for cardiovascular disease. 5-8 A recent metaregression analysis reported a continuous relationship between 2h-postchallenge glucose levels and cardiovascular risk below the diabetic threshold, and there is growing epidemiological evidence for the association of postchallenge hyperglycemia and macrovascular complications. [9] [10] [11] [12] [13] Recently, the Glucose Tolerance in Patients with Acute Myocardial Infarction (GAMI) study revealed that abnormal glucose tolerance, determined by the presence of postchallenge hyperglycemia, was common among patients with AMI and is a risk factor for future cardiovascular events. 14, 15 However, the impact of newly-diagnosed abnor-mal glucose tolerance on the long-term prognosis after AMI has not been fully demonstrated. The aim of the present study, therefore, was to determine whether newlydiagnosed abnormal glucose tolerance affects long-term clinical outcomes after AMI relative to AMI patients with normal glucose tolerance or with previously diagnosed DM in the current clinical settings.
Protocols
The diagnosis of AMI was based on typical chest pain lasting more than 30 min, new Q-waves in at least 2 continuous leads of the standard 12-lead ECG, changes in the electrocardiogram indicating acute ischemia or an increase in creatine kinase (CK) concentration to twice the upper limit of normal range. Serum CK was measured serially every 3 h after admission until a peak value was obtained. The cardiac rehabilitation program for each patient was provided on the 2 nd week after admission.
We analyzed blood glucose concentrations in capillary whole blood immediately after admission. Glycosylated hemoglobin A1c (HbA1c) was measured with a Hi-Auto A1c HA-8121 (Kyoto Kagaku, Kyoto, Japan) on the first morning after admission. In patients without previously diagnosed DM, a standard 75 g oral glucose tolerance test (OGTT) was undertaken at the time of discharge (around the 14 th hospital day). The plasma glucose level was measured using an enzymatic method with a Glucose Analyzer 1140 (Kyoto Daiichi Kagaku, Kyoto, Japan).
The glucometabolic status of each patient before hospitalization was evaluated by reviewing the outpatient records of our own or referring hospitals. Patients were classified as having previously diagnosed DM if they had a history of DM or if they were on a diet or medical treatments for DM. Patients with elevated fasting glucose levels (≥126 mg/dl) at the time of discharge were also categorized as having previously diagnosed DM.
The remaining patients were divided into 2 groups according to their 2-h plasma glucose levels, adopted by the WHO definition from 1998 and the fasting blood glucose criteria adopted by the American Diabetes Association recommendation from 1997. 16, 17 Namely, we classified patients as having newly diagnosed DM if their 2-h post-load plasma glucose concentrations ≥200 mg/dl. IGT was defined as a fasting plasma glucose <126 mg/dl and a 2-h plasma glucose of 140-199 mg/dl. The term newly-diagnosed abnormal glucose tolerance was used to describe the presence of newly-diagnosed DM or IGT. Normal glucose tolerance was defined as a fasting plasma glucose <126 mg/dl and a 2-h blood glucose <140 mg/dl. Impaired fasting glucose (IFG) was defined as a fasting plasma glucose of 110-125 mg/dl. Total cholesterol, high-density lipoprotein-cholesterol and triglyceride levels were measured using standard methods at the time of discharge. The concentration of lowdensity lipoprotein-cholesterol was estimated using the Friedewald equation for subjects who had fasting triglyceride levels <400 mg/dl. 18 Patients who received PCI with stent implantation were started on ticlopidine (100 mg twice a day) and aspirin (81 mg twice a day) for 2 months. All patients were treated according to clinical presentation by their attending physicians without any attention to the results of OGTT during the follow-up period. The patients visited the outpatient clinic monthly for the first 6 months, then every 2 or 3 months until the final visit.
Study Endpoints and Definitions
Cardiovascular death was defined as death from myocardial infarction, stroke or sudden death without any obvious reasons. Acute coronary syndrome (ACS) was defined as a new-onset or worsening angina that required hospitalization and was associated with ischemic ST-segment abnormalities, or any elevation of cardiac enzymes, or both.
Non-fatal myocardial infarction and ACS were defined as non-fatal myocardial infarction or ACS occurring more than 1 month after the primary AMI. The target vessel was considered to be the infarct-related coronary artery that was responsible for the AMI at the time of study enrollment. Target-vessel revascularization (TVR) was defined as coronary intervention of this target vessel. Non-TVR was defined as coronary intervention other than on this target vessel. TVR and non-TVR were considered to be driven by ischemia if the stenosis of any vessel was at least 50% or more of the diameter of the vessel, on the basis of quantitative coronary angiography, in the presence of ischemic signs or symptoms. Congestive heart failure during followup was diagnosed using validated criteria. 19 The primary study endpoint included long-term incidence of a major adverse cardiovascular event (MACE), defined as cardiovascular death, stroke, non-fatal myocardial infarction or ACS, non-TVR either by coronary artery bypass grafting or PCI, and congestive heart failure that required hospitalization.
The principal secondary endpoint included long-term composite clinical incidence of all-cause death, stroke, nonfatal myocardial infarction or ACS, any revascularizations of either target or non-target vessels, congestive heart failure and peripheral vascular disease that required hospitalization.
Statistical Analysis
Demographic and baseline characteristics were tabulated as mean ± SD for continuous variables, and as numbers and percentages for categorical variables. Comparisons among the classified groups -(1) normal glucose tolerance; (2) abnormal glucose tolerance; (3) previously diagnosed DMwere examined using one-way ANOVA for continuous variables and by a chi-square test for categorical variables. In case of significant F values for ANOVA, the Tukey-Kramer test was used for multiple comparisons among groups. Comparisons for postchallenge 2-h glucose levels between normal glucose tolerance and abnormal glucose tolerance were made using the Wilcoxon rank sum test.
We used the Kaplan-Meier method to assess the proportion of patients with events of interest for time-to-event endpoints that included MACE and composite clinical outcomes. Time-to-event among the above 3 groups were compared using a log-rank test. For patients who experienced multiple events, the first event was considered for time-to-event analysis.
In order to examine covariates as possible predictors of MACE, we used a Cox proportional hazard regression model. We modeled candidate predictors as univariates and determined which predictors were significant (p<0.20). Then, all covariates with p values <0.20 were modeled multivariately using a stepwise procedure. The significant threshold for inclusion and exclusion of independent variables was set at 0.20. A 2-sided p value less than 0.05 was considered statistically significant. Statistical analysis was performed using SAS-Stat, software from SAS Institute, Cary, NC, USA.
Results
We enrolled the 275 patients of whom 85 had previously diagnosed DM. The remaining 190 non-DM patients underwent an OGTT at the time of discharge. We completed final visits between September and November 2005. The Among all patients, 34 (12%) had a previous myocardial infarction and 18 (7%) had a history of stroke ( Table 1 ). The patients without previously diagnosed DM were divided into 2 groups: 78 with normal glucose tolerance and 112 patients with newly diagnosed abnormal glucose tolerance (IGT; n=77, DM; n=35). When the fasting plasma glucose criteria were applied, however, only 12% (n=22) of individuals without previously diagnosed DM were diagnosed as IFG. There was only 1 patient with isolated IFG (with no IGT). Among patients with newly-diagnosed abnormal glucose tolerance, only 21 of 112 (19%) showed IFG, so the remaining 81% patients showed isolated postchallenge hyperglycemia.
There were no differences in the prevalence of cardiovascular risk factors or cardiovascular co-morbidity among these 3 groups (Table 1 ). The enzymatic infarct size was similar among 3 groups. Patients with abnormal glucose tolerance showed several differences when compared to patients with normal glucose tolerance. These included higher values of 2-h post-load plasma glucose and triglycerides. The type of reperfusion therapy for AMI was similar among the groups. Subsequent treatments did not differ significantly among the 3 groups except for statin, which was prescribed most frequently in the group with abnormal glucose tolerance ( Table 2) .
Clinical events in relation to glucometabolic status are summarized in Table 3 . Clinical events due to coronary Table 1 . segments that were not responsible for the primary AMI increased after 1 year in patients with abnormal glucose tolerance and those with previously diagnosed DM. As shown in Fig 1, there was a persistent and significant increase in the risk of MACE in patients with abnormal glucose tolerance and those with previous DM. The cardiovascular event-free survival rate in the abnormal glucose tolerance group was 70% at 5-year-follow up, which was significantly lower than the rate in normal glucose tolerance group (87%, p=0.0085) and equivalent to the previously diagnosed DM group (60%, p=0.09). In the abnormal glucose tolerance group, the cardiovascular event-free survival rate was similar between IGT and the newly diagnosed DM subgroups (73% and 67%, p=0.99) at 5-year-follow up. As shown in Fig 2, in all groups, the secondary composite clinical outcome within the first year depended mainly on the repeated revascularization of the primary target vessel that showed restenosis, resulting in rapid deceleration during the first year. Over the following years, however, events related to these target-vessels occurred less frequently. The event-free survival from the secondary composite endpoints in the abnormal glucose tolerance group was 52% at 5-yearfollow up, which was significantly lower than that for the normal glucose tolerance group (72%, p=0.0027) and not much different from the previously diagnosed DM group (44%, p=0.13).
The incidence of MACE was related to several variables identified using a simple Cox regression ( Table 4 ). The best prediction of a future cardiovascular event, according to multiple Cox regression analysis, was achieved using a model that included previous coronary artery bypass surgery, glucometabolic status and prescriptions of statin (Table 4 ). In this Cox model, the relative risk of MACE was 2.65 (95% confidence interval (CI): 1.34-5.15, p=0.004) in the group with abnormal glucose tolerance and 3.27 (95% CI: 1.68-6.38, p=0.0005) in the group with previously diagnosed DM when compared with the normal glucose tolerance group.
Discussion
The present study confirmed that glucometabolic abnormality, as determined by the presence of postchallenge hyperglycemia, was one of the most powerful predictors of long-term cardiovascular events in Japanese patients with AMI, and an OGTT is recommended to identify these patients accurately.
Prevalence of DM and IGT in AMI Patients
The high prevalence (72%) of impaired glucometabolic status (previously diagnosed DM, 31%; and, newly diagnosed abnormal glucose tolerance, 41%) was evident in the present study based on AMI patients in the Japanese population. The actual prevalence might be much higher because we excluded nearly one-third of patients whose medical condition was complicated by in-hospital cardiovascular events and/or renal insufficiency. Conversely, less than 30% of patients were categorized as having normal glucose tolerance as determined by the 75 g OGTT 14 days after the onset of AMI, when their cardiovascular condition was fully stabilized. Therefore, consistent with the data from the GAMI study in Sweden, a substantial proportion of patients with AMI might have abnormal glucose metabolism. 14 Also, the Euro Heart Survey on diabetes and the heart demonstrated that 36% of patients had impaired glucose regulation and 22% had newly detected DM in patients with acute coronary artery disease. 20 Using 134 Japanese patients with AMI/ACS but with no previous DM (normal levels of HbA1c and fasting glucose), Hashimoto et al reported that 10% of subjects had DM and 37% were IGT/IFG using a 75 g OGTT. 21 Taken together, the prevalence of abnormal glucometabolic status in Japanese patients with cardiovascular disease is much higher than we expected, and it may be not much different from that occurring in Caucasian populations. 14 
Prognosis of AMI Patients With Abnormal Glucometabolic Status
The lowest rate of MACE was observed in the group with normal glucose tolerance. More importantly, there were no differences in the MACE rates between newly-diagnosed abnormal glucose tolerance and previously diagnosed DM groups during the long-term follow up after AMI. Our results are consistent with the GAMI study by investigators in Sweden, although there were substantial differences in study populations and backgrounds. 15 These differences included: (1) they did not include subjects with established DM; (2) their undiagnosed DM patients were defined by blood glucose levels less than 200 mg/dl on admission; and (3) most of their patients did not receive acute reperfusion therapy during the course of their AMI. 11 Therefore, racial differences or modest differences in study conditions are not likely to have affected our major finding that the abnormal glucometabolic status is a strong predictor of long-term outcomes. In the present study, patients were evaluated at the first endpoint and repeated cardiovascular events were not considered. DM and asymptomatic fasting hyperglycemia after AMI may increase the risk of the repeated future cardiovascular events. The 5-year mortality of 6.5% in our subjects was equivalent to the 1-year mortality of 6.5% in patients with known DM and random blood glucose <200 mg/dl reported in the Improving Cardiovascular Outcomes in Nova Scotia (ICONS) project. 22 Also, our mortality rate was much lower than that reported as 11% for patients with no previous DM in the GAMI group. 15 However, patients older than 80, with renal insufficiency or in-hospital cardiovascular complications were precluded from the present study. These conditions might have been the cause of decreased mortality among the study subjects. More frequent interventions using acute reperfusion therapy could be another factor underlying the reduced mortality in the present study population.
Early Detection of Abnormal Glucometabolic Status
Our data is consistent with others on the point that patients with postchallenge hyperglycemia carry an increased risk of cardiovascular morbidity and mortality. Early detection of abnormal glucose tolerance would, therefore, permit the initiation of secondary preventive programs in such patients.
The Diabetes Epidemiology Collaborative Analysis of the Diagnostic Criteria in Europe (DECODE) study showed that abnormalities in 2-h glucose were better predictors of mortality from all-cause mortality and from cardiovascular and non-cardiovascular disease than fasting glucose alone. 7, 13 In the present study, 91 patients (81%) with newly-diagnosed abnormal glucose tolerance showed normal fasting plasma glucose levels; hence, less than 20% of patients had apparent IFG. These lines of evidence consistently point to the critical importance of an OGTT assessment of postchallenge hyperglycemia after AMI, although the measurements of fasting plasma glucose and HbA1c still dominate screening in current clinical settings. 23 
Hyperglycemia and Cardiovascular Injury
The STOP-Noninsulin-Dependent Diabetes Mellitus trial demonstrated that decreasing postprandial plasma glucose levels in IGT patients by an -glucosidase inhibitor reduced progression to overt DM as well as the risk of cardiovascular events, which further supported a detrimental role for high blood glucose levels on the cardiovascular system. 24, 25 Ceriello et al and others have shown that postprandial hyperglycemia is associated with an increase in tissue oxidative stress. [26] [27] [28] [29] This appeared to be true not only for DM patients, but also for individuals with IGT. 30, 31 Hyperglycemia-induced oxidative stress might induce endothelial dysfunction, resulting in pathological damage to the cardiovascular system. 32, 33 In the present study, patients with previously diagnosed DM and fasting hyperglycemia were excluded, so we demonstrated a high prevalence of postchallenge hyperglycemia in Japanese patients with AMI, and, patients with postchallenge hyperglycemia after AMI were at high risk of future cardiovascular disease.
In the present study, patients with abnormal glucose tolerance showed higher levels of triglycerides and were prescribed more statins than those with normal glucose tolerance. Since hypertriglyceridemia is one of the established factors contributing to metabolic syndrome, this risk factor together with abnormal glucose tolerance could affect outcomes among patients with AMI. 34, 35 With statistical analyses, the hypertriglyceridemia appeared not to be an independent determinant of long-term prognosis. However, it should be noted that patients with metabolic syndrome could be more common in this particular group.
In the multivariate analysis, glucometabolic status, together with a previous coronary artery bypass surgery and managements without statins, remained as the only risk predictors. However, patients with abnormal glucose tolerance were prescribed more statins than those with normal glucose tolerance. Several large, randomized, controlled trials have demonstrated that cholesterol-lowering therapy with statins reduces the risk of death or cardiovascular events across a wide range of cholesterol levels. [36] [37] [38] In the present study, the attending physician prescribed statins to our patients according to the dosage recommendation in Japan. Recent study revealed that, among patients who have recently had an ACS, an intensive lipid lowering stain regimen provides greater protection against death or major cardiovascular events than does a standard regimen. 39 An intensive lipid-lowering therapy may affect long-term the clinical prognosis in AMI patients with newly diagnosed abnormal glucose tolerance.
We did not include TVR as the primary clinical endpoint in the present study. Actually, the present study shows that coronary events due to progression in segments other than the AMI-responsible lesion are persistently increased after 1 year in patients with abnormal glucose tolerance and those with previously diagnosed DM. Thus, increased MACE rates in these groups are related to the growing number of novel coronary lesions.
Study Limitations
First, abnormal glucose tolerance during admission due to AMI could be influenced by the stress induced by this acute condition. Norhammar et al showed there is an equivalent diagnostic value in the post-load 2-h blood glucose level examined on the third or fourth day of AMI, and at 3 months after discharge. 14 In the present study, the OGTT was performed an average of 14 days after the onset of AMI, when the effects of acute circulating stress and systemic inflammatory processes were likely to be negligible. In addition, most of the patients underwent acute coronary revascularization, which terminated repetitive ischemic attacks.
Second, we excluded 109 (28%) patients, most of whom had major in-hospital complications. It is conceivable that this particular group of patients were had much higher DM rates. In those patients, however, OGTT can not be performed during admission and precise glucometabolic status can not be evaluated. Thus, we assume that the actual frequency of DM was prominent in our patient population.
Third, we did not make repeated evaluations of glucometabolic status. Thus, we do not know how many patients with IGT developed overt DM during the observation period. Although the follow-up study may further elucidate time-dependent changes in glucometabolic status and its effects on the cardiovascular outcome, we feel that it is important to detect abnormal glucose regulations in those patients during the hospital phase. Some reports have shown that baseline IGT is an independent risk predictor for future cardiovascular events, which is not confounded by the subsequent development of diabetes. 40 Lastly, because our subjects were mostly Japanese, caution is needed in extrapolating our results to other ethnic groups. However, we assume that compared to typical Caucasians, our population is exposed to an equivalent risk of an abnormal glucometabolic state and its consequences.
Conclusions
Newly-diagnosed abnormal glucose tolerance predicts long-term cardiovascular events in Japanese patients with AMI. Its adverse prognostic impact is as large as that of previously diagnosed DM. Patients with abnormal glucose tolerance are almost 2.7-fold more likely to have subsequent cardiovascular events during the 5-year-follow up period than those with normal glucose tolerance after AMI. Since patients admitted due to AMI are ideal audiences for life style modulations and risk stratifications, it is incumbent on all physicians who care for these AMI patients not only to revascularize the responsible coronary lesions, but also to utilize this opportunity for the initiation of effective secondary prevention programs.
